Barclays
ORGO icon

Barclays’s Organogenesis Holdings ORGO Stock Holding History

Barclays’s Portfolio ORGO Stock Details ORGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$85.4K Sell
36,052
-70,355
-66% -$244K ﹤0.01% 4092
2025
Q4 		$551K Buy
106,407
+8,697
+9% +$42.1K ﹤0.01% 3786
2025
Q3 		$412K Sell
97,710
-24,842
-20% -$115K ﹤0.01% 3918
2025
Q2 		$449K Buy
122,552
+32,403
+36% +$121K ﹤0.01% 3817
2025
Q1 		$389K Sell
90,149
-20,766
-19% -$83.8K ﹤0.01% 3680
2024
Q4 		$355K Buy
110,915
+16,106
+17% +$54K ﹤0.01% 4028
2024
Q3 		$271K Buy
94,809
+67,855
+252% +$190K ﹤0.01% 4141
2024
Q2 		$75.5K Sell
26,954
-22,306
-45% -$59.9K ﹤0.01% 4037
2024
Q1 		$140K Sell
49,260
-46,942
-49% -$160K ﹤0.01% 4297
2023
Q4 		$393K Buy
96,202
+70,926
+281% +$199K ﹤0.01% 4023
2023
Q3 		$80.4K Buy
25,276
+11,284
+81% +$35.9K ﹤0.01% 3677
2023
Q2 		$46.5K Sell
13,992
-88,836
-86% -$263K ﹤0.01% 3872
2023
Q1 		$219K Sell
102,828
-3,963
-4% -$9.79K ﹤0.01% 3734
2022
Q4 		$287K Buy
106,791
+67,203
+170% +$196K ﹤0.01% 3649
2022
Q3 		$129K Buy
39,588
+19,548
+98% +$88.3K ﹤0.01% 3421
2022
Q2 		$98K Sell
20,040
-32,041
-62% -$197K ﹤0.01% 3782
2022
Q1 		$397K Sell
52,081
-6,582
-11% -$50.9K ﹤0.01% 3043
2021
Q4 		$543K Buy
58,663
+9,766
+20% +$104K ﹤0.01% 3167
2021
Q3 		$696K Buy
48,897
+11,311
+30% +$176K ﹤0.01% 3001
2021
Q2 		$626K Buy
37,586
+14,941
+66% +$279K ﹤0.01% 2943
2021
Q1 		$413K Buy
22,645
+9,503
+72% +$129K ﹤0.01% 3289
2020
Q4 		$99K Sell
13,142
-1,458
-10% -$6.92K ﹤0.01% 4142
2020
Q3 		$56K Sell
14,600
-1,847
-11% -$7.29K ﹤0.01% 4540
2020
Q2 		$64K Buy
16,447
+7,151
+77% +$25.8K ﹤0.01% 4803
2020
Q1 		$30K Sell
9,296
-7,028
-43% -$30.1K ﹤0.01% 5489
2019
Q4 		$79K Buy
16,324
+11,130
+214% +$70.5K ﹤0.01% 5582
2019
Q3 		$34K Sell
5,194
-1,597
-24% -$8.89K ﹤0.01% 6072
2019
Q2 		$52K Sell
6,791
-4,038
-37% -$29.7K ﹤0.01% 6072
2019
Q1 		$81K Buy
+10,829
New +$216K ﹤0.01% 5529

Other funds holding ORGO

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Barclays's ORGO Position: Q1 2026 in Review

Barclays reduced its Organogenesis Holdings (ORGO) stake by 66% in Q1 2026, selling an estimated $244K and leaving 36,052 shares worth $85.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4092.

Barclays first reported a position in ORGO in Q1 2019 and has held it in 29 quarters since. The position peaked at $696K in Q3 2021. 121 funds tracked by Wall St. Rank hold ORGO as of Q1 2026.

  • Barclays held 36,052 shares of Organogenesis Holdings worth $85.4K as of Q1 2026.
  • Barclays sold 70,355 Organogenesis Holdings shares in Q1 2026, an estimated $244K.
  • Organogenesis Holdings made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4092 holding.
  • Barclays first reported a position in Organogenesis Holdings in Q1 2019 and has held it in 29 quarters since.
  • Barclays's Organogenesis Holdings position peaked at $696K in Q3 2021.
  • 121 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.